Update on primary hypobetalipoproteinemia

Current Atherosclerosis Reports

Volumn 16, Issue 7, 2014, Pages

  Hooper, Amanda J ^a,b,c   Burnett, John R ^a,b  

^a ROYAL PERTH HOSPITAL   (Australia)

^b UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^c UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

Author keywords

Abetalipoproteinemia; Apolipoprotein B; Chylomicron retention disease; Combined hypolipidemia; Familial hypobetalipoproteinemia; Hypobetalipoproteinemia; Low density lipoprotein

Indexed keywords

ABETALIPOPROTEINEMIA; ANGPTL3 GENE; APOB GENE; ARTICLE; CHYLOMICRON RETENTION DISEASE; DNA SEQUENCE; FAMILIAL COMBINED HYPOLIPIDEMIA; FAMILIAL HYPOBETALIPOPROTEINEMIA; GENE; GENE SEQUENCE; HUMAN; LIPOPROTEIN DEFICIENCY; MTTP GENE; PCSK9 GENE; SAR1B GENE; WESTERN BLOTTING; AVITAMINOSIS; COMPLICATION; GENETICS; HYPOBETALIPOPROTEINEMIA, FAMILIAL, APOLIPOPROTEIN B; HYPOBETALIPOPROTEINEMIAS; LOW FAT DIET;

ALPHA TOCOPHEROL; RETINOL; VITAMIN;

ABETALIPOPROTEINEMIA; AVITAMINOSIS; DIET, FAT-RESTRICTED; HUMANS; HYPOBETALIPOPROTEINEMIA, FAMILIAL, APOLIPOPROTEIN B; HYPOBETALIPOPROTEINEMIAS; VITAMIN A; VITAMIN E; VITAMINS;

EID: 84901203045     PISSN: 15233804     EISSN: 15346242     Source Type: Journal    
DOI: 10.1007/s11883-014-0423-3     Document Type: Article

References (56)

1. Hooper AJ, van Bockxmeer FM, Burnett JR. Monogenic hypocholesterolaemic lipid disorders and apolipoprotein B metabolism. Crit Rev Clin Lab Sci. 2005;42:515-45. (Pubitemid 43068251)
2. Burnett JR, Bell DA, Hooper AJ, Hegele RA. Clinical utility gene card for: abetalipoproteinaemia. Eur J Hum Genet. 2012. doi:10.1038/ejhg.2012.30.
3. Burnett JR, Bell DA, Hooper AJ, Hegele RA. Clinical utility gene card for: familial hypobetalipoproteinaemia (APOB). Eur J Hum Genet. 2012. doi:10.1038/ejhg.2012.85.
4. Cohen JC, Boerwinkle E, Mosley Jr TH, Hobbs HH. Sequence variations in PCSK9, low LDL, and protection against coronary heart disease. N Engl J Med. 2006;354:1264-72.
5. Cohen J, Pertsemlidis A, Kotowski IK, Graham R, Garcia CK, Hobbs HH. Low LDL cholesterol in individuals of African descent resulting from frequent nonsense mutations in PCSK9. Nat Genet. 2005;37:161-5.
6. Hooper AJ, Marais AD, Tanyanyiwa DM, Burnett JR. The C679X mutation in PCSK9 is present and lowers blood cholesterol in a Southern African population. Atherosclerosis. 2007;193:445-8. (Pubitemid 47058112)
7. Peretti N, Sassolas A, Roy CC, et al. Guidelines for the diagnosis and management of chylomicron retention disease based on a review of the literature and the experience of two centers. Orphanet J Rare Dis. 2010;5:24.
8. Hooper AJ, Burnett JR. Recent developments in the genetics of LDL deficiency. Curr Opin Lipidol. 2013;24:111-5.
9. Musunuru K, Pirruccello JP, Do R, et al. Exome sequencing, ANGPTL3 mutations, and familial combined hypolipidemia. N Engl J Med. 2010;363:2220-7.
10. Wetterau JR, Aggerbeck LP, Bouma ME, et al. Absence of microsomal triglyceride transfer protein in individuals with abetalipoproteinemia. Science. 1992;258:999-1001.
11. Shoulders CC, Brett DJ, Bayliss JD, et al. Abetalipoproteinemia is caused by defects of the gene encoding the 97 kDa subunit of a microsomal triglyceride transfer protein. Hum Mol Genet. 1993;2: 2109-16. (Pubitemid 24003406)
12. Hussain MM, Rava P, Walsh M, Rana M, Iqbal J. Multiple functions of microsomal triglyceride transfer protein. Nutr Metab (Lond). 2012;9:14.
13. Ohashi K, Ishibashi S, Osuga J, et al. Novel mutations in the microsomal triglyceride transfer protein gene causing abetalipoproteinemia. J Lipid Res. 2000;41:1199-204. (Pubitemid 30666884)
14. Rehberg EF, Samson-Bouma ME, Kienzle B, et al. A novel abetalipoproteinemia genotype. Identification of a missense mutation in the 97-kDa subunit of the microsomal triglyceride transfer protein that prevents complex formation with protein disulfide isomerase. J Biol Chem. 1996;271:29945-52. (Pubitemid 26389631)
15. Berriot-Varoqueaux N, Aggerbeck LP, Samson-Bouma M, Wetterau JR. The role of the microsomal triglyceride transfer protein in abetalipoproteinemia. Annu Rev Nutr. 2000;20:663-97.
16. Kane JP, Havel RJ. Disorders of the biogenesis and secretion of lipoproteins containing the B apolipoproteins. In: Scriver CR, Beaudet AL, Sly WS, Scriver CR, Beaudet AL, Sly WS, editors. The metabolic and molecular bases of inherited disease. New York: McGraw-Hill; 2001. p. 2717-52.
17. Delpre G, Kadish U, Glantz I, Avidor I. Endoscopic assessment in abetalipoproteinemia (Bassen-Kornzweig-syndrome). Endoscopy. 1978;10:59-62. (Pubitemid 8280478)
18. Tanyel MC, Mancano LD. Neurologic findings in vitamin E deficiency. Am Fam Physician. 1997;55:197-201. (Pubitemid 27034712)
19. Zamel R, Khan R, Pollex RL, Hegele RA. Abetalipoproteinemia: two case reports and literature review. Orphanet J Rare Dis. 2008;3: 19.
20. •• Lee J, Hegele RA. Abetalipoproteinemia and homozygous hypobetalipoproteinemia: a framework for diagnosis and management. J Inherit Metab Dis. 2014. doi:10.1007/s10545-013-9665-4. This article discusses the diagnosis, assessment, treatment, and follow-up of ABL and homozygous FHBL.
21. Chowers I, Banin E, Merin S, Cooper M, Granot E. Long-term assessment of combined vitamin A and E treatment for the prevention of retinal degeneration in abetalipoproteinaemia and hypobetalipoproteinaemia patients. Eye. 2001;15:525-30. (Pubitemid 32755726)
22. Muller DP. Vitamin E, and neurological function. Mol Nutr Food Res. 2010;54:710-8.
23. Kayden HJ, Hatam LJ, Traber MG. The measurement of nanograms of tocopherol from needle aspiration biopsies of adipose tissue: normal and abetalipoproteinemic subjects. J Lipid Res. 1983;24:652-6. (Pubitemid 13059198)
24. Clarke MW, Hooper AJ, Headlam HA, Wu JH, Croft KD, Burnett JR. Assessment of tocopherol metabolism and oxidative stress in familial hypobetalipoproteinemia. Clin Chem. 2006;52:1339-45. (Pubitemid 43956026)
25. Schonfeld G, Lin X, Yue P. Familial hypobetalipoproteinemia: genetics and metabolism. Cell Mol Life Sci. 2005;62:1372-8. (Pubitemid 40853825)
26. Tarugi P, Averna M. Hypobetalipoproteinemia: genetics, biochemistry, and clinical spectrum. Adv Clin Chem. 2011;54:81-107.
27. Whitfield AJ, Barrett PHR, van Bockxmeer FM, Burnett JR. Lipid disorders and mutations in the APOB gene. Clin Chem. 2004;50: 1725-32. (Pubitemid 39298000)
28. Burnett JR, Shan J,Miskie BA, et al. A novel nontruncating APOB gene mutation, R463W, causes familial hypobetalipoproteinemia. J Biol Chem. 2003;278:13442-52. (Pubitemid 36800118)
29. Burnett JR, Zhong S, Jiang ZG, et al.Missense mutations in APOB within the betaalpha1 domain of human APOB-100 result in impaired secretion of apoB and apoB-containing lipoproteins in familial hypobetalipoproteinemia. J Biol Chem. 2007;282:24270-83. (Pubitemid 47328026)
30. Zhong S, Magnolo AL, Sundaram M, et al. Nonsynonymous mutations within APOB in human familial hypobetalipoproteinemia - evidence for feedback inhibition of lipogenesis and post-endoplasmic reticulum degradation of apolipoprotein B. J Biol Chem. 2010;285:6453-64.
31. Elias N, Patterson BW, Schonfeld G. Decreased production rates of VLDL triglycerides and apoB-100 in subjects heterozygous for familial hypobetalipoproteinemia. Arterioscler Thromb Vasc Biol. 1999;19:2714-21. (Pubitemid 29536048)
32. Yao ZM, Blackhart BD, Linton MF, Taylor SM, Young SG, McCarthy BJ. Expression of carboxyl-terminally truncated forms of human apolipoprotein B in rat hepatoma cells. Evidence that the length of apolipoprotein B has amajor effect on the buoyant density of the secreted lipoproteins. J Biol Chem. 1991;266:3300-8. (Pubitemid 21909208)
33. Lambert G, Sjouke B, Choque B, Kastelein JJ, Hovingh GK. The PCSK9 decade. J Lipid Res. 2012;53:2515-24.
34. Zhao Z, Tuakli-Wosornu Y, Lagace TA, et al. Molecular characterization of loss-of-function mutations in PCSK9 and identification of a compound heterozygote. Am J Hum Genet. 2006;79:514-23. (Pubitemid 44384260)
35. Cariou B, Ouguerram K, Zair Y, et al. PCSK9 dominant negative mutant results in increased LDL catabolic rate and familial hypobetalipoproteinemia. Arterioscler Thromb Vasc Biol. 2009;29:2191-7.
36. Ogata H, Akagi K, Baba M, et al. Fatty liver in a case with heterozygous familial hypobetalipoproteinemia. Am J Gastroenterol. 1997;92:339-42. (Pubitemid 27076490)
37. Schonfeld G, Patterson BW, Yablonskiy DA, et al. Fatty liver in familial hypobetalipoproteinemia: triglyceride assembly into VLDL particles is affected by the extent of hepatic steatosis. J Lipid Res. 2003;44:470-8. (Pubitemid 37279694)
38. Sankatsing RR, Fouchier SW, de Haan S, et al. Hepatic and cardiovascular consequences of familial hypobetalipoproteinemia. Arterioscler Thromb Vasc Biol. 2005;25:1979-84. (Pubitemid 41243472)
39. Tanoli T, Yue P, Yablonskiy D, Schonfeld G. Fatty liver in familial hypobetalipoproteinemia: roles of the APOB defects, intra-abdominal adipose tissue, and insulin sensitivity. J Lipid Res. 2004;45:941-7. (Pubitemid 38552865)
40. Visser ME, Lammers NM, Nederveen AJ, et al. Hepatic steatosis does not cause insulin resistance in people with familial hypobetalipoproteinaemia. Diabetologia. 2011;54:2113-21.
41. Hooper AJ, Adams LA, Burnett JR. Genetic determinants of hepatic steatosis in man. J Lipid Res. 2011;52:593-617.
42. Lonardo A, Tarugi P, Ballarini G, Bagni A. Familial heterozygous hypobetalipoproteinemia, extrahepatic primary malignancy, and hepatocellular carcinoma. Dig Dis Sci. 1998;43:2489-92. (Pubitemid 28531325)
43. Tarugi P, Lonardo A, Ballarini G, et al.Astudy of fatty liver disease and plasma lipoproteins in a kindred with familial hypobetalipoproteinemia due to a novel truncated form of apolipoprotein B (APO B-54.5). J Hepatol. 2000;33:361-70. (Pubitemid 30663372)
44. Jones B, Jones EL, Bonney SA, et al. Mutations in a Sar1 GTPase of COPII vesicles are associated with lipid absorption disorders. Nat Genet. 2003;34:29-31. (Pubitemid 36548786)
45. Siddiqi SA, Gorelick FS, Mahan JT, Mansbach 2nd CM. COPII proteins are required for Golgi fusion but not for endoplasmic reticulum budding of the pre-chylomicron transport vesicle. J Cell Sci. 2003;116:415-27. (Pubitemid 36163881)
46. Peretti N, Roy CC, Sassolas A, et al. Chylomicron retention disease: a long term study of two cohorts.Mol GenetMetab. 2009;97: 136-42.
47. Nakajima K, Kobayashi J, Mabuchi H, et al. Association of angiopoietin-like protein 3 with hepatic triglyceride lipase and lipoprotein lipase activities in human plasma. Ann Clin Biochem. 2010;47:423-31.
48. Shan L, Yu XC, Liu Z, et al. The angiopoietin-like proteins ANGPTL3 and ANGPTL4 inhibit lipoprotein lipase activity through distinct mechanisms. J Biol Chem. 2009;284:1419-24.
49. Fazio S, Sidoli A, Vivenzio A, et al. A form of familial hypobetalipoproteinaemia not due to a mutation in the apolipoprotein B gene. J Intern Med. 1991;229:41-7.
50. Minicocci I, Montali A, Robciuc MR, et al. Mutations in the ANGPTL3 gene and familial combined hypolipidemia: a clinical and biochemical characterization. J Clin Endocrinol Metab. 2012;97:E1266-75.
51. Minicocci I, Santini S, Cantisani V, et al. Clinical characteristics and plasma lipids in subjects with familial combined hypolipidemia: a pooled analysis. J Lipid Res. 2013;54:3481-90.
52. .• Robciuc MR, Maranghi M, Lahikainen A, et al. Angptl3 deficiency is associated with increased insulin sensitivity, lipoprotein lipase activity, and decreased serum free fatty acids. Arterioscler Thromb Vasc Biol. 2013;33:1706-13. This article shows that although partial deficiency of ANGPTL3 did not affect lipase activity, complete deficiency decreased the levels of free fatty acids and improved insulin sensitivity.
53. .•• Minicocci I, Cantisani V, Poggiogalle E, et al. Functional and morphological vascular changes in subjects with familial combined hypolipidemia: an exploratory analysis. Int J Cardiol. 2013;168: 4375-8. Despite an approximately 50% reduction in the concentration of LDL cholesterol, ANGPTL3 homozygotes had increased CIMT.
54. Noto D, Cefalu AB, Valenti V, et al. Prevalence of ANGPTL3 and APOB gene mutations in subjects with combined hypolipidemia. Arterioscler Thromb Vasc Biol. 2012;32:805-9.
55. Ouguerram K, Zair Y, Kasbi-Chadli F, et al. Low rate of production of apolipoproteins B100 and AI in 2 patients with Anderson disease (chylomicron retention disease). Arterioscler Thromb Vasc Biol. 2012;32:1520-5.
56. .•• Johansen CT, Dube JB, Loyzer MN, et al. LipidSeq: a next-generation clinical resequencing panel for monogenic dyslipidemias. J Lipid Res. 2014;55:765-72. This article describes the design and performance of a targeted resequencing panel which has potential to aid in molecular diagnosis of dyslipidemias, including primary HBL.